If You Don’t Take a Position in this Marijuana Stock, You May Regret It

Here's a marijuana stock with rising large players volume that you may regret not taking a long position in. Then again, maybe not.

This company has developed the world's first prescription marijuana medicine that's now approved in many countries outside the United States.

This company's cannabis-formulated drug could generate peak annual sales of around $3 billion. At that rate, the stock could see its earnings jump a whopping 2,900% in the first year alone.

Gilead Sciences Wins FDA Approval For Biktarvy

Gilead Sciences looks like a good oversold, candle over candle setup.

Gilead Sciences received approval from the FDA for Biktarvy, a once-daily combination of three drugs (bictegravir /emtricitabine/tenofovir alafenamide or BIC/FTC/TAF) for the treatment of HIV-1 infection. The company stands to reap up to a potential $5 billion in sales revenue from the approval.
Continue reading “Gilead Sciences Wins FDA Approval For Biktarvy”

Antares Pharma PDUFA On Rising Large Players Volume

Antares Pharma has had a few set backs over the years and investors have waited patiently for the company to turn a profit.

Antares Pharma stock is seeing a strong run up in large players volume going into the February PDUFA for the Makena auto injector. Will 2018 finally be the year that this small-cap company turns a profit?

Is Ionis Pharmaceuticals Stock Ready To Explode Higher?

The chart of Ionis Pharmaceuticals doesn’t look like much but the fundamentals show eye-popping revenue growth.

Will 2018 be the year that Ionis Pharmaceuticals' stock explodes higher?

Synergy Pharmaceuticals Ahead of PDUFA

Synergy Pharmaceuticals has a PDUFA ruling coming within the next couple of days. The Twiggs Money Flow has started to run ahead of the FDA announcement.

Synergy Pharmaceuticals stock is starting to run higher ahead of its PDUFA date. Find out if you should be playing this stock for a quick pop.

Ablynx Stock Explodes Higher As Large Players Volume Rises

Ablynx stock is a late-stage clinical development company that is finally going to bring a product to market in Germany in 2018.

Summary

  • 2018 is the year that Ablynx brings Caplacizumab to market in Germany.
  • Novo Nordisk made an unsolicited bid for the company that was rejected.
  • Large players volume and the Twiggs Money Flow are surging higher.